Despite United Therapeutics Corp.'s best efforts to put a positive spin on its oral pulmonary arterial hypertension (PAH) program by highlighting a recent in-licensing deal for Eli Lilly and Co.'s late-stage tadalafil, the company's shares sank 35 percent on a Phase III miss with its own oral PAH drug. (BioWorld Today) Read More